Cellular and Molecular Life Sciences,
Год журнала:
2024,
Номер
81(1)
Опубликована: Авг. 28, 2024
Chronic
hepatitis
B
virus
(HBV)
infection
is
a
global
health
problem
that
substantially
increases
the
risk
of
developing
liver
disease.
The
development
novel
strategy
to
induce
anti-HB
seroconversion
and
achieve
long-lasting
immune
response
against
chronic
HBV
remains
challenging.
Here,
we
found
affected
signaling
pathway
involved
in
STING-mediated
induction
host
responses
dendritic
cells
(DCs)
then
generated
lymph
node-targeted
nanovaccine
co-delivered
surface
antigen
(HBsAg)
cyclic
diguanylate
monophosphate
(c-di-GMP)
(named
PP-SG
nanovaccine).
feasibility
efficiency
for
CHB
treatment
were
evaluated
HBV-carrier
mice.
Serum
samples
analyzed
HBsAg,
anti-HBs,
DNA,
alanine
aminotransferase
levels,
DNA
RNA
HBcAg,
accompanied
by
an
analysis
HBV-specific
cellular
humoral
during
treatment.
increased
phagocytosis
DC
maturation,
efficiently
safely
eliminated
HBV,
achieved
reinjection,
disrupted
infection-induced
tolerance,
as
characterized
generation
multifunctionality
CD8